|
|
|
XNCR Description — Xencor, Inc
Xencor is a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. Co. is developing a portfolio of clinical-stage XmAb® drug candidates from its protein engineering technology platforms. Co.'s XmAb bispecific Fc drug candidates include: Vudalimab (XmAb717), which is a bispecific antibody that targets PD-1 and CTLA-4 and for patients with metastatic castration-resistant prostate cancer and other solid tumor types; and Plamotamab, which is a bispecific antibody that targets CD20, an antigen on B-cell tumors, and CD3, an activating receptor on T cells.
Company Name: |
Xencor, Inc |
Website: |
www.xencor.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding XNCR: |
55 |
Total Market Value Held by ETFs: |
$359,028,096.6 |
Total Market Capitalization: |
$1,346,000,000 |
% of Market Cap. Held by ETFs: |
26.67% |
|
ETF |
XNCR Weight |
XNCR Amount |
IJR |
0.12% |
$95,114,519 |
VTI |
0.00% |
$43,928,462 |
VB |
0.03% |
$35,423,989 |
IWM |
0.05% |
$32,855,672 |
XBI |
0.34% |
$25,718,429 |
VXF |
0.02% |
$20,735,758 |
VBK |
0.06% |
$19,787,232 |
SPSM |
0.12% |
$12,445,732 |
IJS |
0.12% |
$8,453,106 |
IJT |
0.13% |
$7,098,650 |
List of all 55 ETFs holding XNCR
» |
|
|
|
|
Strong Buy (3.53 out of 4)
60th percentile
|
|
|